Garon EB, Ciuleanu TE, Arrieta O , Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second -line treatment of stage IV non -small cell lung cancer after disease progression on platinum -based therapy (REVEL): a multicenter, double -blind, randomized phase 3 trial. Lancet.